Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients

Katrin Reiter, MSc, Max Hubmann, MD, Egor Harin, Sebastian Vosberg, Kathrin Bräundl, Bianka Ksienzyk, Stephanie Schneider, PhD, Annika Maria Dufour, PhD, Evelyn Zellmeier, Stefan K. Bohlander, MD, Christina Sauerland, Dipl.-Math, Wolfgang E Berdel, MD, Bernhard J Wörmann, MD, Thomas Büchner, MD, Jan Braess, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Philipp A. Greif, MD

Blood (2016) 128 (22): 1682.

https://doi.org/10.1182/blood.V128.22.1682.1682

Published: 2016

Journal Articles

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Jan-Henrik Mikesch, MD, Christina Sauerland, Dipl.-Math, Tobias Herold, MD, Dennis Görlich, Eike Bormann, Wolfgang Hartmann, MD, Christoph Schliemann, MD, Bernhard J Wörmann, MD, Wolfgang Hiddemann, Karsten Spiekermann, MD, Matthias Stelljes, Utz Krug, MD, Carsten Muller-Tidow, MD, Thomas Büchner, MD, Wolfgang E Berdel, MD, Maria Francisca Arteaga, PhD

Blood (2016) 128 (22): 2840.

https://doi.org/10.1182/blood.V128.22.2840.2840

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)

Michele Pohlen, MD, Christoph Groth, MD, Tim Sauer, MD, Dennis Görlich, Rolf Mesters, MD, Christoph Schliemann, MD, Georg Lenz, MD, Carsten Müller-Tidow, MD, Thomas Büchner, MD, Wolfgang E Berdel, MD, Matthias Stelljes, MD

Blood (2015) 126 (23): 2025.

https://doi.org/10.1182/blood.V126.23.2025.2025

Published: 2015

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

Journal Articles

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Nikola P Konstandin, Klaus H. Metzeler, MD, Annika Dufour, PhD, Philipp A Greif, MD, Tobias Herold, MD, Bianka Ksienzyk, Stephanie Schneider, Dr. rer. nat., Wolfgang E Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Cristina Sauerland, MSc, Jan Braess, MD, Wolfgang Hiddemann, MD, Stefan K Bohlander, MD, Karsten Spiekermann, MD

Blood (2014) 124 (21): 2385.

https://doi.org/10.1182/blood.V124.21.2385.2385

Published: 2014

Journal Articles

An Optimized Risk Stratification Model in Acute Promyelocytic Leukemia Identifies Patients with an Exceptionally Good Prognosis Regarding the Incidence of Relapse

Anna Hecht, MD, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, MD, Thomas Büchner, MD, Karsten Spiekermann, MD, Christel Weiss, Wolf-Karsten Hofmann, Eva Lengfelder, MD, Florian Nolte

Blood (2014) 124 (21): 72.

https://doi.org/10.1182/blood.V124.21.72.72

Published: 2014

Journal Articles

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Bernhard J. Woermann, MD, Maria Cristina Sauerland, MSc, Achim Heinecke, PhD, Utz Krug, MD, Wolfgang Hiddemann, MD

Blood (2014) 124 (21): 2267.

https://doi.org/10.1182/blood.V124.21.2267.2267

Published: 2014

Journal Articles

A 16-Gene Signature Associated with High Levels of Wilms Tumor-1 ( WT1 ) Expression Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Ahmadreza Niavarani, MD PhD, Tobias Herold, MD, Yasmin Reyal, MD PhD, Erin Currie, MSc, Stuart Horswell, PhD, Arash Jalali, PhD, Maria Cristina Sauerland, MSc, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Stefan K Bohlander, PhD, Reza Malekzadeh, MD AGAF, Peter J.M. Valk, PhD, Dominique Bonnet, PhD

Blood (2014) 124 (21): 1021.

https://doi.org/10.1182/blood.V124.21.1021.1021

Published: 2014

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Hanna Janke, Friederike Schneider, MD, Daniela Schumacher, Tobias Herold, MD, Hopfner Karl-Peter, PhD, Stephanie Schneider, PhD, Wolfgang E. Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Marion Subklewe, MD, Stefan K. Bohlander, MD, Wolfgang Hiddemann, MD, Harald Polzer, PhD, Karsten Spiekermann, MD

Blood (2013) 122 (21): 1312.

https://doi.org/10.1182/blood.V122.21.1312.1312

Published: 2013

Journal Articles

A Risk Score Integrating BAALC, ERG and WT1 Expression Can Be Used To Improve Risk Stratification In Acute Promyelocytic Leukemia

Anna Hecht, Florian Nolte, MD, Daniel Nowak, MD, Verena Nowak, Benjamin Hanfstein, MD, Thomas Büchner, MD, Karsten Spiekermann, MD, Wolf-Karsten Hofmann, MD, Eva Lengfelder, MD

Blood (2013) 122 (21): 1323.

https://doi.org/10.1182/blood.V122.21.1323.1323

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Blood (2013) 122 (21): 1447.

https://doi.org/10.1182/blood.V122.21.1447.1447

Published: 2013

Journal Articles

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Utz Krug, Claudia Haferlach, MD, Susanne Schnittger, PhD, Matthias Stelljes, MD, Gerda Silling, MD, Peter Staib, MD, Andreas Grueneisen, MD, Albrecht Reichle, Leopold Balleisen, MD, Hartmut Eimermacher, MD, Aristoteles Giagounidis, MD, Herbert Rasche, MD, Eva Lengfelder, MD, Cristina Sauerland, MSc, Achim Heinecke, PhD, Bernhard Josef Woermann, MD, Wolfgang Hiddemann, MD, PhD

Blood (2012) 120 (21): 1509.

https://doi.org/10.1182/blood.V120.21.1509.1509

Published: 2012

Journal Articles

Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study

Meir Wetzler, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD, PhD, Herve Dombret, Hartmut Döhner, Prof. Dr. med., Sylvain Pilorge, Utz Krug, MD, Richard A. Larson, MD, Guido Marcucci, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD, Clara D. Bloomfield, MD

Blood (2011) 118 (21): 2521.

https://doi.org/10.1182/blood.V118.21.2521.2521

Published: 2011

Journal Articles

In Acute Promyelocytic Leukemia (APL) Low BAALC Gene Expression Identifies a Group of Patients with Favorable Outcome in Overall Survival and Relapse Free Survival,

Florian Nolte, MD, Anna Hecht, Daniel Nowak, MD, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, MD, Thomas Buchner, MD, Karsten Spiekermann, MD, Cristina Sauerland, Wolf-Karsten Hofmann, MD, Eva Lengfelder, MD

Blood (2011) 118 (21): 3543.

https://doi.org/10.1182/blood.V118.21.3543.3543

Published: 2011

Journal Articles

Impact of Resilience, Anxiety and Depression on Quality of Life Assessment in Patients with Acute Myeloic Leukemia After Allogeneic Stem Cell Transplantation

Susanne Amler, MSc, Christian Deiters, Cristina Sauerland, MSc, Joachim Kienast, Thomas Buchner, MD, Andrea Schumacher, PhD

Blood (2011) 118 (21): 2088.

https://doi.org/10.1182/blood.V118.21.2088.2088

Published: 2011

Journal Articles

Inferior Outcome in Patients with Acute Promyelocytic Leukemia and High Expression of the Ets Related Gene : Role in Leukemogenesis and Potential Implications for Future Therapeutic Approaches?,

Anna Hecht, Florian Nolte, MD, Daniel Nowak, MD, Verena Nowak, Benjamin Hanfstein, MD, Andreas Faldum, MD, Thomas Buchner, MD, Karsten Spiekermann, MD, Cristina Sauerland, Eva Lengfelder, MD, Wolf-Karsten Hofmann, MD

Blood (2011) 118 (21): 3531.

https://doi.org/10.1182/blood.V118.21.3531.3531

Published: 2011

Journal Articles

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Blood (2011) 118 (21): 425.

https://doi.org/10.1182/blood.V118.21.425.425

Published: 2011

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

NARROW

Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

An Optimized Risk Stratification Model in Acute Promyelocytic Leukemia Identifies Patients with an Exceptionally Good Prognosis Regarding the Incidence of Relapse

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

A 16-Gene Signature Associated with High Levels of Wilms Tumor-1 ( WT1 ) Expression Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

A Risk Score Integrating BAALC, ERG and WT1 Expression Can Be Used To Improve Risk Stratification In Acute Promyelocytic Leukemia

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study

In Acute Promyelocytic Leukemia (APL) Low BAALC Gene Expression Identifies a Group of Patients with Favorable Outcome in Overall Survival and Relapse Free Survival,

Impact of Resilience, Anxiety and Depression on Quality of Life Assessment in Patients with Acute Myeloic Leukemia After Allogeneic Stem Cell Transplantation

Inferior Outcome in Patients with Acute Promyelocytic Leukemia and High Expression of the Ets Related Gene : Role in Leukemogenesis and Potential Implications for Future Therapeutic Approaches?,

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only